CRL

Business profile & competitive position

Charles River Laboratories International, Inc. operates in the Healthcare sector, specifically the Medical – Diagnostics & Research industry. The company describes itself as a full-service, non-clinical global drug development partner. Its three reportable segments are Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions, and it supports clients from target identification through non-clinical development and product release. In 2025, total revenue was $4.0 billion, with DSA contributing 59.8% of sales, Manufacturing contributing 19.1%, and RMS contributing 21.1%. The company currently runs more than 120 sites across over 20 countries.

The current financial return metrics tell a mixed story about competitive position. A trailing net margin of -6.0% and ROE of -7.7% show that, on a reported basis, Charles River has not earned its cost of equity recently even though it is a leading player in its niche. Negative margins and returns can occur in contract research organizations when fixed capacity is underutilized, pricing pressure rises, or one-time charges hit reported earnings. Still, the business is not currently converting revenue into positive bottom-line returns, which limits the read-through on any durable moat from these figures alone. High barriers to entry in GLP and non-GLP safety assessment may support strategic positioning over time, but the latest numbers show abrasion rather than a clear profitability edge.

Financial posture

Charles River carries a $17.3 billion market capitalization against a trailing P/E of -74.3. A negative P/E ratio means the market is assigning value to a business that is currently unprofitable on a net basis. The net margin of -6.0% and ROE of -7.7% confirm the same point: earnings are negative, so traditional profitability per-share valuation metrics cannot be interpreted in the usual “multiple of earnings” way.

The company’s beta of 1.40 is above the market average of 1.0, which means the stock has historically moved more sharply than the broad market. That fits the Diagnostics & Research group, where sentiment around biopharma R&D budgets, study volume, and regulatory news can move share prices quickly. With the price at $359.41, the RSI at 68.1 sits close to commonly watched overbought thresholds, and the stock is trading well above its 50-day exponential moving average of $304.10. Those technical inputs describe a stock that has outperformed its short-term trend, but they do not, by themselves, make an investment case.

Strategic priorities & outlook

The company’s most recent 10-K lays out a clear near-term agenda. Charles River plans to optimize its global footprint by closing or consolidating approximately 12 additional sites over the next two years, mostly in DSA and RMS. It also intends to integrate Discovery Services and Safety Assessment into one combined DSA organization, with a unified sales force and leadership structure. Operationally, the goal is to become the “scientific partner of choice” by offering a comprehensive and integrated portfolio that speeds biomedical research and therapeutic innovation. In the Manufacturing Solutions segment, management continues to look for ways to expand Biologics Testing Solutions services and facilities in the U.S. and Europe.

On the M&A front, Charles River acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, in January 2026. The stated purpose is to support DSA supply operations and RMS third-party sales. Taken together, the plan combines footprint rationalization, segment integration, biologics testing expansion, and selective sourcing deals. Those actions are consistent with a management team trying to lower the cost base, deepen the relationship with large biopharma clients, and secure inputs for research-model-dependent operations.

Macro & geopolitical exposure

Because Charles River sits in Medical – Diagnostics & Research, its macro exposure starts with biopharma R&D spending and regulatory policy. Non-clinical drug development is not recession-proof; when pharmaceutical and biotechnology clients cut early-stage pipelines, demand for discovery services, safety assessment studies, and research models can slow. Conversely, a stronger funding environment for biotech startups tends to flow through to study volume and animal-model demand.

Regulatory exposure is also meaningful. GLP and non-GLP toxicology work is governed by FDA and international health authority standards, and any changes to safety testing requirements would directly affect backlog and pricing. Animal-source supply chains are sensitive to ethical, environmental, and disease-related regulation; recent non-human primate sourcing has faced scrutiny across the sector and is not immune. Currency risk is real as well, given operations across more than 20 countries. Trade policy and cross-border logistics can affect both imported research materials and the cost of moving samples and products between facilities. Finally, rate and credit conditions influence clients’ ability to fund early-stage research and Charles River’s own capacity to finance site consolidation or acquisitions.

Recent developments

Several recent headlines place the stock in context heading into its next report.

• October 28, 2026 (zacks.com): “Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?”
• October 28, 2026 (seekingalpha.com): “Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts”
• October 27, 2026 (businesswire.com): “Charles River Leverages Virtual Control Groups in GLP Studies”
• October 27, 2026 (defenseworld.net): “Charles River Laboratories International (NYSE:CRL) Director James Foster Sells 24,042 Shares of Company Stock”

The Zacks headline notes that the market’s real expectation is for earnings growth, while the Seeking Alpha headline signals institutional activity by mentioning Ariel Appreciation Fund’s third-quarter positioning. The Business Wire report on virtual control groups is a technology and efficiency angle that could matter for study design, costs, and regulatory acceptability over time. The Defense World report documents insider activity: director James Foster sold 24,042 shares on October 27. Insider sales alone do not prove a directional view, but they are worth noting alongside valuation and momentum data.

Earnings behavior & post-earnings drift

Charles River has beaten earnings estimates in each of the last eight reported quarters, a 100% beat rate, with an average surprise of 9.3%. The average five-day price move after those reports has been +1.24%, classified as an upward post-earnings drift. That said, the most recent quartet shows the pattern is far from uniform.

• August 5, 2026: Actual EPS of $3.02 versus the $2.74 estimate, a 10.2% surprise. The stock rose 1.84% the next day and 9.07% over the following five days.
• May 7, 2026: Actual EPS of $2.06 versus the $1.96 estimate, a 5.1% surprise. The stock fell 2.23% the next day and 12.42% over the following five days.
• February 18, 2026: Actual EPS of $2.39 versus the $2.33 estimate, a 2.6% surprise. The stock rose 3.95% the next day and 6.05% over the following five days.
• November 5, 2025: Actual EPS of $2.43 versus the $2.32 estimate, a 4.7% surprise. The stock rose 1.9% the next day and 2.27% over the following five days.

The next scheduled earnings release is November 4, 2026 before market open, with consensus EPS of $2.97. Even with the strong historical beat rate, the May 2026 reaction shows that beating estimates is not enough by itself to guarantee a positive post-earnings move; guidance, segment commentary, and the stock’s position going into the print can shift the reaction sharply. The unofficial consensus is $2.97, so investors will be focused on whether Charles River can extend the eight-quarter streak and what management says about site consolidation, DSA integration, and biologics testing traction.

For a deeper dive into how institutional analysts are currently interpreting these figures, readers should review the full institutional verdict and consensus outlook for CRL.